About this trial

Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies

Eligibility criteria

Qualifiers

Patients with H. pylori infection;

Aged 18-65 years.

Disqualifiers

Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;

Conditions unsuitable for performance of gastroscopy, such as coagulopathy, impaired renal function;

Pregnancy or breastfeeding;

Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Trial design

Treatments tested in this trial

  • biopsy
  • H. pylori eradication

Treatment groups

300 Participants
are divided into 1 treatment group

Locations

1
Department of Gastroenterology, Qilu Hospital, Shandong University250012, JinanShandong, China

Sponsors and collaborators

Shandong University

Lead sponsor